Golf Clap for RTI Biologics

RTI Biologics (Nasdaq: RTIX  ) reported earnings on Feb. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), RTI Biologics met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share was unchanged.

Gross margins expanded, operating margins shrank, net margins dropped.

Revenue details
RTI Biologics recorded revenue of $44.6 million. The eight analysts polled by S&P Capital IQ expected sales of $45.1 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.04. The eight earnings estimates compiled by S&P Capital IQ forecast $0.04 per share. GAAP EPS of $0.04 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 48.8%, 260 basis points better than the prior-year quarter. Operating margin was 8.0%, 40 basis points worse than the prior-year quarter. Net margin was 5.1%, 40 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $46.0 million. On the bottom line, the average EPS estimate is $0.05.

Next year's average estimate for revenue is $188.5 million. The average EPS estimate is $0.22.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 209 members out of 219 rating the stock outperform, and 10 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.96.

Looking for alternatives to RTI Biologics? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.

• Add RTI Biologics to My Watchlist.